{
    "root": "0b6a7f92-a2a0-4821-9a85-295996ce245e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fyavolv",
    "value": "20250203",
    "ingredients": [
        {
            "name": "ETHINYL ESTRADIOL",
            "code": "423D2T571U"
        },
        {
            "name": "NORETHINDRONE ACETATE",
            "code": "9S44LIC7OJ"
        },
        {
            "name": "CALCIUM STEARATE",
            "code": "776XM7047L"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TOCOPHEROL",
            "code": "R0ZB2556P8"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": "fyavolv combination estrogen progestin indicated woman uterus : treatment moderate severe vasomotor symptoms due menopause ( 1.1 ) prevention postmenopausal osteoporosis ( 1.2 )",
    "contraindications": "one tablet orally daily ( 2.1 , 2.2 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "undiagnosed abnormal genital bleeding ( 4 , 5.2 ) breast cancer history breast cancer ( 4 , 5.2 ) estrogen-dependent neoplasia ( 4 , 5.2 ) active dvt , pe , history conditions ( 4 , 5.1 ) active arterial thromboembolic disease ( example , stroke myocardial infarction ) , history conditions ( 4 , 5.1 ) known anaphylactic reaction , angioedema , hypersensitivity fyavolv ( 4 ) hepatic impairment disease ( 4 , 5.10 ) protein c , protein , antithrombin deficiency , known thrombophilic disorders ( 4 )",
    "indications_original": "Fyavolv is a combination of an estrogen and progestin indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Prevention of Postmenopausal Osteoporosis ( 1.2 )",
    "contraindications_original": "One tablet orally once daily ( 2.1 , 2.2 )",
    "adverseReactions_original": "Undiagnosed abnormal genital bleeding ( 4 , 5.2 ) Breast cancer or a history of breast cancer ( 4 , 5.2 ) Estrogen-dependent neoplasia ( 4 , 5.2 ) Active DVT, PE, or history of these conditions ( 4 , 5.1 ) Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions ( 4 , 5.1 ) Known anaphylactic reaction, angioedema, or hypersensitivity to Fyavolv ( 4 ) Hepatic impairment or disease ( 4 , 5.10 ) Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders ( 4 )"
}